Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.

Related Videos
Related Content